Xenon Pharmaceuticals (XENE) Change in Cash (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Change in Cash data on file, last reported at $346.7 million in Q1 2026.

• On a quarterly basis, Change in Cash rose 1430.66% year-over-year to $346.7 million in Q1 2026; TTM through Mar 2026 was $429.2 million, a 643.08% increase from a year earlier, with the FY2025 full-year figure at $56.5 million, up 1051.8% from the prior year.
• Change in Cash for Q1 2026 stood at $346.7 million, up from $94.6 million in the prior quarter.
• Over the last five years, Change in Cash for XENE reached as high as $346.7 million in Q1 2026 and fell as low as -$266.5 million in Q3 2022.
• Historically, Change in Cash has averaged $21.8 million across 5 years, with a median of $12.3 million in 2023.
• On a YoY basis, Change in Cash climbed as much as 5113.77% in 2022 and fell as far as 5562.14% in 2022.
• Year by year, Change in Cash stood at -$46.2 million in 2022, then soared by 206.1% to $49.1 million in 2023, then advanced by 12.27% to $55.1 million in 2024, then jumped by 71.8% to $94.6 million in 2025, then surged by 266.3% to $346.7 million in 2026.
• Per Business Quant data, the three most recent Change in Cash figures were $346.7 million in Q1 2026, $94.6 million in Q4 2025, and -$30.9 million in Q3 2025.